Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00466804
Other study ID # DAIT CTOT-05
Secondary ID
Status Completed
Phase N/A
First received April 25, 2007
Last updated December 31, 2015
Start date June 2007
Est. completion date July 2011

Study information

Verified date December 2015
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Data and Safety Monitoring BoardUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Injury of transplant tissue by a transplant recipient's immune system continues to be the leading cause of graft rejection and recipient death. The purpose of this study is to identify a single test or a combination of noninvasive tests currently used for heart transplant monitoring that correlate to long-term graft survival.


Description:

A major cause of heart transplant failure is the blockage of blood flow from lesions caused by ongoing injury and repair of the graft by the host's immune system. However, the role of T cells, antibodies, and other parts of the recipient's immune system are not well understood in transplant injury. Currently, there are no effective, noninvasive ways to detect or predict how an individual's immune system will react to a transplant. The purpose of this study is to correlate current noninvasive monitoring tests with long-term graft survival and function, and determine which tests are the most accurate predictors of this survival.

Participants in this study must currently be on the waiting list for a heart transplant and have a donor heart available to them. This study will consist of six study visits over 12 months. The baseline visit will occur on the day of transplantation. Follow-up visits will occur at Week 6 and Months 3, 6, 9, and 12 post-transplant. At each visit, a physical exam, medication tracking, assessment of graft survival, and blood and urine collection will occur. At the Week 6 and Month 12 visits, intravascular ultrasound and echocardiograms will occur. At the Week 6, Month 6, and Month 12 visits, endomyocardial biopsies will also occur. No immunosuppressive therapy will be provided by the study.


Recruitment information / eligibility

Status Completed
Enrollment 263
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers No
Gender Both
Age group 10 Years and older
Eligibility Inclusion Criteria:

- Age greater than 10 and a body mass of 30 kg (66 lbs) or more

- On waiting list for a heart transplant for whom a donor heart available

- Willing to comply with study protocol

- Willing to use acceptable forms of contraception

- Parent or guardian willing to provide consent, if applicable

Exclusion Criteria:

- Receiving multiple organ transplants

- Previously received organ transplants

- Other comorbidities that, in the opinion of the site investigator, would interfere with the study

- Currently taking immunosuppression for nontransplant reasons

- Participation in an interventional clinical trial

- Pregnancy or breastfeeding

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Heart transplant
People in this study will have a heart transplant and be monitored for signs of rejection

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Northwestern University Medical School Chicago Illinois
United States The Cleveland Clinic Foundation Cleveland Ohio
United States Medical City Dallas Hospital Dallas Texas
United States Loyola University School of Medicine Maywood Illinois
United States Mount Sinai School of Medicine New York New York
United States Beth Israel Medical Center Newark New Jersey
United States University of Utah, LDS Hospital Salt Lake City Utah
United States University of Utah, VACM.LDS Salt Lake City Utah
United States University of California San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trials in Organ Transplantation, National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Jiang S, Lechler RI. CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm Allergy Drug Targets. 2006 Dec;5(4):239-42. Review. — View Citation

Starling RC, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH, Kobashigawa J, McCurry K, Marboe C, Mehra MR, Zuckerman A, Deng MC; Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant. 2006 Dec;25(12):1389-95. Review. Erratum in: J Heart Lung Transplant. 2007 Feb;26(2):204. — View Citation

Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS; CTOT-05 consortium. Multicenter Analysis of Immune Biomarkers and He — View Citation

Zheng XX, Sánchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity. 2003 Oct;19(4):503-14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Composite Measure of Transplant Health A composite of incidence of the following:
Death,
Re-transplantation or re-listed for transplantation,
Biopsy proven acute rejection (BPAR) of > 2R,
Episode of rejection associated with hemodynamic compromise,
Coronary artery vasculopathy defined by a change in MIT of >0.5 mm between study entry and 12 months.
12 months after enrollment in study Yes
See also
  Status Clinical Trial Phase
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Active, not recruiting NCT05096299 - OCS Heart EXPAND + CAP Continued Follow-Up
Completed NCT02323321 - International EXPAND Heart Pivotal Trial N/A
Not yet recruiting NCT05025774 - Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Completed NCT03150095 - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates N/A
Active, not recruiting NCT02554578 - Impact of mHealth in Heart Transplant Management N/A
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Active, not recruiting NCT05741723 - OCS DCD Heart + CAP Continued Follow-Up
Completed NCT03831048 - Donors After Circulatory Death Heart Trial N/A
Completed NCT04615182 - Donor After Circulatory Death Heart CAP Trial N/A
Completed NCT02597543 - Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction Phase 4
Recruiting NCT05824364 - Exercise aNd hEArt Transplant N/A
Enrolling by invitation NCT05390411 - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial N/A
Recruiting NCT04770012 - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Phase 3
Terminated NCT01769443 - Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation Phase 2
Recruiting NCT06426173 - Effect of Resistance Training in Patients on the Waiting List for Heart Transplant N/A
Not yet recruiting NCT05459181 - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) N/A
Terminated NCT01485757 - Prospective L-arginine Study Phase 1
Active, not recruiting NCT01186250 - Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation Phase 2